P740: PK, PD AND SAFETY OF FIRST-IN-HUMAN, FIRST-IN-CLASS PHASE I TRIAL (AUR103-101; BHARAT) OF AUR103, AN ORAL CD47 INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES
Manjunath Krishnappa,
Divyesh Mandavia,
Minish Jain,
Mukesh S,
Ankit Patel,
Anshul Agarwal,
Sanjeev Giri,
Nirbhay Kumar Tiwari,
Saravanan Thiyagarajan,
Mamon Dey,
Gutta Padmanabha Naidu,
Murali Ramachandra,
Akhil Kumar
Affiliations
Manjunath Krishnappa
1 Aurigene Oncology Limited, Bangalore, India
Divyesh Mandavia
1 Aurigene Oncology Limited, Bangalore, India
Minish Jain
2 Ruby Hall Clinic, Pune, India
Mukesh S
3 Mysore Medical College And Research Institute Road, Mysuru, India
Ankit Patel
4 Unique Hospital, Surat, India
Anshul Agarwal
5 Kiran Hospital and Research Center, Surat, India
